Form 4: Nuvalent Director Anna Protopapas Granted Equity Awards

Nuvalent, Inc. Director Anna Protopapas was granted 2,647 restricted stock units and options to purchase 4,147 shares of Class A Common Stock, effective June 18, 2025, as part of her compensation.

Summary

• Anna Protopapas, a Director of Nuvalent, Inc. (NUVL), was granted equity awards.
• The awards include 2,647 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs), granted at a price of $0.00, representing the right to receive one share of common stock per RSU.
• Additionally, she was granted stock options to purchase 4,147 shares of Class A Common Stock with an exercise price of $75.53 per share, granted at a price of $0.00.
• Both the RSUs and stock options vest in full on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, contingent upon her continued service to the company.
• Following these transactions, Ms. Protopapas beneficially owns 5,146 shares of Class A Common Stock directly and 4,147 stock options directly.

Sentiment

Score: 6

Explanation: Slightly positive as it represents standard director compensation, aligning interests with shareholders, and does not indicate any negative operational or financial news.

Positives

• The grant of equity awards to a director aligns their interests with those of shareholders, encouraging long-term commitment and performance.
• The awards are part of standard director compensation, indicating stable corporate governance practices.

Negatives

• The issuance of new shares upon vesting of RSUs and exercise of options could lead to minor dilution for existing shareholders, though this is typical for equity compensation.

Risks

• The value of the granted equity awards is subject to the future performance of Nuvalent, Inc.'s stock price. If the stock price declines, the value of the RSUs and options may decrease or become worthless (for options if price drops below exercise price).
• Vesting of the awards is contingent on continued service, meaning the director must remain with the company to realize the full benefit.

Future Outlook

The document indicates future vesting events for the granted equity awards, contingent on continued service, with the earliest vesting date being June 18, 2026, or the date of the next annual meeting of stockholders.

Industry Context

The grant of equity awards to directors is a common practice in the biotechnology and pharmaceutical industry, including companies like Nuvalent, Inc., to attract and retain talent, and to align the interests of directors with long-term shareholder value creation. This filing reflects a routine compensation event for a director.

Comparison to Industry Standards

• This type of equity grant (RSUs and stock options) to a non-employee director is a standard component of compensation packages across publicly traded companies, particularly in high-growth sectors like biotechnology.
• While specific grant sizes vary based on company size, stage, and individual director responsibilities, the structure aligns with common practices seen at comparable biopharmaceutical companies.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Anna Protopapas, a director of Nuvalent, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential minor dilution from the future issuance of shares upon vesting and exercise, but also improved alignment of director incentives with long-term shareholder value.
• Employees: No direct impact mentioned, but standard equity compensation practices can positively influence overall company culture and talent retention.

Next Steps

• Vesting of 2,647 Restricted Stock Units on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders.
• Vesting of options to purchase 4,147 shares of Class A Common Stock on the earlier of June 18, 2026, or the date of Nuvalent, Inc.'s next annual meeting of stockholders.

Key Dates

Keywords

Nuvalent Inc., NUVL, SEC Form 4, insider transaction, equity grant, restricted stock units, RSUs, stock options, director compensation, beneficial ownership, corporate governance